Substance / Medication

Semaglutide

Overview

Active Ingredient
semaglutide
RxNorm CUI
1991302

Indications

WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: Limitations of Use Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. • To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fata

Labeler: Novo NordiskUpdated: 2026-01-30T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

• 5.1 13.1 [see Warnings and Precautions (), Nonclinical Toxicology ()] In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcin

Contraindications

When this intervention should not be used

WEGOVY is contraindicated in the following conditions: • 5.1 [see Warnings and Precautions ()] A personal or family history of MTC or in patients with MEN 2. • 5.7 [see Warnings and Precautions ()] A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY injecti

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

62 trials linked to this intervention

62
Total Trials
41
Recruiting
11
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review.
Mandal Laura, Andersen Louise Udby, Luef Birgitte Møller et al. · Eur J Obstet Gynecol Reprod Biol · 2026
PMID: 41313865Meta-Analysis
The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.
Ala Moein, Moheb Aleaba Mohammadreza · J Endocrinol Invest · 2025
PMID: 39347905Meta-Analysis
Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.
Cleto André Saad, Schirlo João Matheus, Beltrame Mayara et al. · Int J Obes (Lond) · 2025
PMID: 39396098Meta-Analysis
Cardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Sobral Milene Vitória Sampaio, Rodrigues Livia Kneipp, Barbosa Abner Mácola Pacheco et al. · Am J Cardiovasc Drugs · 2025
PMID: 39907981Meta-Analysis
Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.
Hashmi Tallal Mushtaq, Ahmed Mushood, Haider Ali et al. · Clin Transl Sci · 2025
PMID: 39930946Meta-AnalysisFull text (PMC)
Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews.
Hu Xiaoye, Wang Yongsheng, Yang Kehu et al. · Endocrine · 2025
PMID: 39955702Meta-Analysis
Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.
Hamayal Muhammad, Akhtar Chaudhary Humayun, Ahmad Naveed et al. · Am J Cardiovasc Drugs · 2025
PMID: 40106161Meta-Analysis
Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.
Wen Jimmy, Syed Burhaan, Nadora Denise et al. · Endocrinol Diabetes Metab · 2025
PMID: 40184508Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Semaglutide (substance)
SNOMED CT
764283003
UMLS CUI
C3885068
RxNorm CUI
1991302
Labeler
Novo Nordisk

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
62
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.